Abstract:Objective: To investigate the level of mycophenolate acid (MPA) exposure in renal allograft recipients receiving mycophenolate mofetil (MMF) as maintenance immunosuppressive therapy. Methods: Sixty renal allograft recipients were treated with cyclosporine A (CsA), MMF and prednisone (Pred), peripheral vein blood samples were obtained 0.5 h, 2 h and 4 h after administration of MMF, the plasma concentrations of MPA were measured by enzyme-multiplied immunoassay technique. The values of area under the curve (AUC) of plasma MPA concentration (MPA AUC) of the renal allograft recipients were calculated by the simplified formula of limited sampling strategy. All recipients were divided into low dose MMF group (MMF<1.5 g/d, n=18), recommendation dose group (MMF=1.5 g/d, n=29) and high dose MMF group (MMF>1.5 g/d, n=13) according to doses of oral administration of MM F. Besides, all recipients were divided into low exposure to MPA group (MPA AUC<30 mg·h·L -1), target exposure to MPA group (MPA AUC=30-60 mg·h·L -1) and high exposure to MPA group (MPA AUC>60 mg·h·L -1) according to values of MPA AU C.Results: The mean MPA AUC of 60 renal transplant recipients was (59.83±19.42) mg·h·L -1. There were 3 cases (5.0%) in low exposure to MPA group, 31 cases (51.7%) in target exposure to MPA group and 26 cases (43.3%) in high exposure to MPA group. The mean doses of CsA in low exposure to MPA group, target exposure to MPA group and high exposure to MPA group were (166.67±14.43) mg/d, (137.10±41.27) mg/d and (128.85±37.88) mg/d respectively, exhibiting a decreasing tendency, while there was no significant difference among groups (P>0.05). Conclusion: Under the condition of MMF dose adjustment based on clinical events without MPA AUC monitoring, MPA tends to be highly exposed in renal allograft recipients. There are significant inter-individual variations in MPA pharmacokinetics, and it is necessary to perform MMF monitoring in treatment for renal allograft recipients.

Pharmacokinetics Study of Mycophenolate Mofetil in Renal Transplantation Patients

Pharmacokinetics of Mycophenolic Acid in Chinese Kidney Transplant Patients

Pharmacokinetics of Mycophenolic Acid in Renal Transplant Patients after First-Dosing and in Steady-State

Investigation on Pharmacokinetics of Mycophenolic Acid in Chinese Adult Renal Transplant Patients.

Population Pharmacokinetics of Mycophenolic Acid in Renal Transplant Patients: A Comparison of the Early and Stable Posttransplant Stages

Pharmacokinetics Of Mycophenolic Acid In Chinese Patients With Liver Transplant (In Chinese) (Vol 41, Pg 1157, 2006)

Pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolite in renal transplant recipients at steady state

Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients

Population Pharmacokineties of Mycophenolic Acid in Chinese Adult Renal Transplant Patients

Limited Sampling Strategy for Mycophenolic Acid in Chinese Kidney Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus During the Early Posttransplantation Phase

Clinical Pharmacokinetics of Mycophenolic Acid of Recipients in the Early Period of Orthotopic Liver Transplantation

Cyclosporine A and Tacrolimus Combined with Enteric-Coated Mycophenolate Sodium Influence the Plasma Mycophenolic Acid Concentration - a Randomised Controlled Trial in Chinese Live Related Donor Kidney Transplant Recipients

Pharmacokinetics of mycophenolate mofetil in adult Chinese patients with autoimmune disease

Relationship Between Pharmacokinetics and Pharmadynamics of Mycophenolic Acid in Liver Transplant Recipients

Correlation Between Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid in Liver Transplant Patients.

Relationship between mycophenolate mofetil dose and mycophenolate acid exposure in renal allograft recipients during maintenance immunosuppressive therapy

Therapeutic Drug Monitoring of Mycophenolic Acid in Chinese Renal Allograft Recipients

Limited Sampling Strategy for the Estimation of Mycophenolic Acid Area under the Plasma Concentration-Time Curve in Adult Patients Undergoing Liver Transplant.

Impact of MPA Pharmacokinetics on MMF-Related Side Effects

Short-Term Intensified Dosage Regimen of Mycophenolic Acid is Associated with Less Acute Rejection in Kidney Transplantation from Donation after Circulatory Death.

Development and Application of HPLC Method in Simultaneous Determination of Mycophenolic Acid and Its 7-O-glucuronide Metabolite in Human Plasma